Refine by
Tumor Tissue Articles & Analysis
42 news found
Transcranial techniques are improving neurological diagnostics, while tumor tissue-based technology is revolutionizing cancer treatment, particularly in prostate cancer screening. ...
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). ...
This tissue microarray includes various artery tissues (coronary, aorta, etc.) and atherosclerosis samples. ...
Through this partnership, we aim to provide researchers with the tools and expertise needed to accelerate their research efforts in developing liver models for drug discovery, accurate cancer models for precision medicine, and exploring the potential of combining light and extrusion bioprinting modalities to advance tissue engineering.” Prof. Shaochen Chen added, ...
ByCELLINK
Here below, discover our top three bestselling kits and find the perfect solution for your sample prep! P000912-LYSK1-A.0 Soft tissue homogenizing CK14 The CK14 kit is the perfect solution for soft tissue homogenization, like brain, liver, kidney, skin, plant leaves, mammalian cells and more. Compatible with Precellys Evolution Touch, Precellys 24 Touch and ...
Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the advantages of small molecular weight, high tumor penetration, low immunogenicity, large-scale synthesis using solid phase synthesis, low production cost, relatively good pharmacokinetics, and so on. Peptides selected for PDCs can specifically target protein receptors overexpressed in ...
The publications addressed that the majority of druggable targets that drive oncogenic vulnerability are not expressed in a uniform or homogeneous manner throughout tumor tissue. Thus, intratumoral heterogeneity, as observed among the cells of an individual tumor, poses a major challenge in targeted therapy selection in oncology practice. ...
Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay. Using our molecular counting technology, the assay provides absolute quantification of methylated circulating tumor DNA (ctDNA) burden. ...
The majority of PROTACs were created with ligands that recruit E3 ligases, which are widely expressed in tumors and normal tissues, and these PROTACs can cause off-target toxicity if the target protein is not tumor-specific. The development of tumor-specific/selective PROTACs will benefit from identifying those E3 ligases that ...
“Our MOS technology supports the development of new insights into tumor microenvironments and heterogeneity of the originating tumor tissue for accurate, rapid and high-throughput therapeutic profiling. ...
Biomarkers have been shown to help identify patients who are most likely to benefit from treatment with immunotherapies, such as PD-1/PD-L1-targeted therapies. Still, the gold standard of tumor tissue PD-L1 staining, as well as other biomarkers, such as tumor mutational burden, do not always accurately predict the efficacy of these therapies in ...
About FoundationOne®CDx FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using ...
The test integrates genomic and epigenomic signatures to detect disease without the need for tumor tissue. (Abstract 168) Additionally, clinical utility data will demonstrate that the Guardant360® liquid biopsy test detects microsatellite instability-high (MSI-H) status in patients with advanced gastrointestinal cancers at a similar frequency to ...
The test looks for hundreds of biomarkers in a small amount of tumor tissue, including complex genomic signatures like tumor mutational burden (TMB), homologous recombination deficiency (HRD) and microsatellite instability (MSI) that can determine whether immunotherapy or PARP inhibitors would work for a patient. ...
About FoundationOne CDx FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA ...
If at least 1 of 5 demonstrates the presence of LB-100 in tumor tissue, 3 additional subjects will be enrolled. If at least 2 of the 8 patients demonstrate LB-100 in tumor tissue, the study will be considered significant providing further support for studying if the addition of LB-100 to standard treatment regimens for malignant ...
All patients were heavily pretreated with a median of 4 lines of prior systemic treatment. 16 patients were evaluable for tumor response analysis according to RECIST 1.1 with at least one post-treatment tumor assessment at the time of data cut-off. ...
Under the new agreements, TRICARE beneficiaries now have improved access to Foundation Medicine’s FDA-approved comprehensive genomic profiling (CGP) tests, FoundationOne®CDx and FoundationOne®Liquid CDx, in accordance with their approved indications for all solid tumors. Through tissue or blood samples, FoundationOne CDx and FoundationOne Liquid ...
“TK-8001 is a novel CD8 TCR-T targeting MAGE-A1, a tumor-specific antigen associated with aggressive cancers and poor clinical prognosis,” stated Eugen Leo, Chief Medical Officer of T-knife. “The presentations at SITC will cover important aspects of our work related with TK-8001, including favorable preclinical data comparing TK-8001 to human donor-derived TCRs, ...
Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific's Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify non-small cell lung cancer (NSCLC) patients whose tumors carry epidermal growth factor receptor (EGFR) Exon20-insertion mutations for potential treatment with RYBREVANT (amivantamab-vmjw)*, Janssen Biotech, ...